When is the use of intravenous immunoglobulin appropriate in immune thrombocytopenia?
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19817 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Sydney Dubois und 8 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Hôpital Henri Mondor, Assistance Publique-Hôpitau…. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Intravenous immunoglobulin (IVIg) is the gold standard treatment for severe cases of immune thrombocytopenia (ITP). However, its cost, limited duration of efficacy and market supply tension have led French guidelines to reserve IVIg for ITP patients with formal contra‐indications to corticosteroids, with French bleeding score (‘Khellaf score’) > 8, and corticosteroid‐resistant patients either with Khellaf score ≤ 8 or in preparation for an invasive procedure or during pregnancy. We studied the prescribing practices of IVIg for ITP in real‐life conditions and assessed their compliance with French guidelines. A monocentric retrospective study was conducted between 2016 and 2020 among 114 patients hospitalized in our unit, for a total of 208 IVIg treatments. In 37% of cases, the Khellaf score was >8, validating IVIg prescription according to French guidelines. In the remaining cases, reasons noted for use of IVIg included corticosteroid resistance (33.7%), preparation for an invasive procedure (8.5%), context of pregnancy (6.6%) and contra‐indication to corticosteroids (3.3%). After analysis, IVIg prescription was considered valid according to current French guidelines in 84.4% of cases. Non‐compliant IVIg prescription was more frequent in younger patients ( p = 0.027). Concomitant anti‐coagulation was also noted as an argument for IVIg prescription outside of the current French guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Department, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, Fran…
- Department of Hematology, Centre Henri Becquerel, Rouen, France.
- Université Paris-Est Créteil, INSERM, IMRB, Creteil, France.
- Public Health Department & Clinical Research Unit, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Creteil, France.
- Pharmacy Department, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France.
- Clinical Epidemiology and Ageing (CEpiA) Unit EA7376, Université Paris-Est Créteil (UPEC), Créteil, France.
ORCID-Profile: Sydney Dubois, Matthieu Mahevas, Bertrand Godeau
Zitieren
APA
Dubois, S., Layese, R., Limal, N., Languille, L., Kini-Matondo, W., Mahevas, M., Michel, M., Audureau, E., & Godeau, B. (2024). When is the use of intravenous immunoglobulin appropriate in immune thrombocytopenia?. British Journal of Haematology. https://doi.org/10.1111/bjh.19817
Vancouver
Dubois S, Layese R, Limal N, Languille L, Kini-Matondo W, Mahevas M, et al. When is the use of intravenous immunoglobulin appropriate in immune thrombocytopenia?. British Journal of Haematology. 2024. doi:10.1111/bjh.19817
BibTeX
@article{Dubois2024,
author = {Dubois, Sydney and Layese, Richard and Limal, Nicolas and Languille, Laetitia and Kini-Matondo, Willy and Mahevas, Matthieu and Michel, Marc and Audureau, Etienne and Godeau, Bertrand},
title = {When is the use of intravenous immunoglobulin appropriate in immune thrombocytopenia?},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19817}
}
EUVIMED